AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $1.39 billion. The enterprise value is $1.49 billion.
Important Dates
The next estimated earnings date is Thursday, February 26, 2026, after market close.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 27.69 million shares outstanding. The number of shares has increased by 7.36% in one year.
| Current Share Class | 27.69M |
| Shares Outstanding | 27.69M |
| Shares Change (YoY) | +7.36% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 3.05% |
| Owned by Institutions (%) | 69.94% |
| Float | 15.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.72 |
| Forward PS | 7.66 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.68
| Current Ratio | 8.68 |
| Quick Ratio | 8.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.37 |
Financial Efficiency
Return on equity (ROE) is -308.02% and return on invested capital (ROIC) is -4.66%.
| Return on Equity (ROE) | -308.02% |
| Return on Assets (ROA) | -4.23% |
| Return on Invested Capital (ROIC) | -4.66% |
| Return on Capital Employed (ROCE) | -9.10% |
| Weighted Average Cost of Capital (WACC) | 8.47% |
| Revenue Per Employee | $1.25M |
| Profits Per Employee | -$622,279 |
| Employee Count | 136 |
| Asset Turnover | 0.40 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AnaptysBio has paid $77,000 in taxes.
| Income Tax | 77,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +244.58% in the last 52 weeks. The beta is 0.35, so AnaptysBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +244.58% |
| 50-Day Moving Average | 46.81 |
| 200-Day Moving Average | 31.11 |
| Relative Strength Index (RSI) | 57.34 |
| Average Volume (20 Days) | 385,705 |
Short Selling Information
The latest short interest is 5.57 million, so 20.11% of the outstanding shares have been sold short.
| Short Interest | 5.57M |
| Short Previous Month | 5.14M |
| Short % of Shares Out | 20.11% |
| Short % of Float | 35.09% |
| Short Ratio (days to cover) | 10.53 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $169.47 million and -$84.63 million in losses. Loss per share was -$2.88.
| Revenue | 169.47M |
| Gross Profit | 16.47M |
| Operating Income | -28.68M |
| Pretax Income | -84.55M |
| Net Income | -84.63M |
| EBITDA | -28.10M |
| EBIT | -28.68M |
| Loss Per Share | -$2.88 |
Full Income StatementBalance Sheet
The company has $248.96 million in cash and $346.45 million in debt, with a net cash position of -$97.49 million or -$3.52 per share.
| Cash & Cash Equivalents | 248.96M |
| Total Debt | 346.45M |
| Net Cash | -97.49M |
| Net Cash Per Share | -$3.52 |
| Equity (Book Value) | -29.42M |
| Book Value Per Share | -1.07 |
| Working Capital | 292.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$144.97 million and capital expenditures -$349,000, giving a free cash flow of -$145.32 million.
| Operating Cash Flow | -144.97M |
| Capital Expenditures | -349,000 |
| Free Cash Flow | -145.32M |
| FCF Per Share | -$5.25 |
Full Cash Flow StatementMargins
Gross margin is 9.72%, with operating and profit margins of -16.92% and -49.94%.
| Gross Margin | 9.72% |
| Operating Margin | -16.92% |
| Pretax Margin | -49.89% |
| Profit Margin | -49.94% |
| EBITDA Margin | -16.58% |
| EBIT Margin | -16.92% |
| FCF Margin | n/a |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.36% |
| Shareholder Yield | -7.36% |
| Earnings Yield | -6.08% |
| FCF Yield | -10.45% |
Analyst Forecast
The average price target for AnaptysBio is $60.18, which is 19.79% higher than the current price. The consensus rating is "Buy".
| Price Target | $60.18 |
| Price Target Difference | 19.79% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 32.45% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of -1.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.06 |
| Piotroski F-Score | 3 |
